Stockreport
InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting [Yahoo! Finance]
Last inflarx n.v. earnings: 8/14 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations: inflarx.com/home/investors/press-releases/01-2018--inflarx-to-present-at-upcoming-investor-conferences.html
anti-inflammatory therapeutics targeting the complement system, today announced the presentation of multiple posters describing the utility of vilobelimab in pyoderma gangrenosum (PG) and hidradenitis suppurativa (HS), including clinical efficacy data, safety assessments, and pharmacokinetic (PK) and pharmacodynamic (PD) analyses. These data are being presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting being held March 7 - 11, in Orlando, FL. Camilla Chong, MD, Chief Medical Officer of InflaRx , commented: “At AAD 2025, we presented multiple data sets we believe collectively paint a broad and positive picture of vilobelimab's potential in addressing inflammatory conditions such as hidradenitis suppurativa and pyoderma gangrenosum. Multiple safety analyses showed vilobelimab to be well-tolerated in HS, and in the rare and devastating disease of PG, in which patients are often very ill and have co-morbidities. We also presented data showing vilobelimab can reduc
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | IFRX | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
IFRX alerts
IFRX alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
IFRX alerts
High impacting InflaRx N.V. news events
Weekly update
A roundup of the hottest topics
IFRX
NEWS
NEWS
- InflaRx (NASDAQ: IFRX) had its price target raised by analysts at Guggenheim from $7.00 to $10.00. They now have a "buy" rating on the stock.[MarketBeat]
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.[MarketBeat]
- InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones[GlobeNewswire]
- InflaRx (NASDAQ: IFRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.[MarketBeat]
- InflaRx Showcases Vilobelimab’s Role in Immuno-Dermatology at the 2025 AAD Annual Meeting[GlobeNewswire]
- More
IFRX
SEC Filings
SEC Filings
- 4/3/25 - Form 6-K
- 3/20/25 - Form 20-F
- 3/20/25 - Form 6-K
- IFRX's page on the SEC website
- More